References
- Lambertini M, Richard F, Nguyen B, et al. Ovarian function and fertility preservation in breast cancer: should gonadotropin-releasing hormone agonist be administered to all premenopausal patients receiving chemotherapy? Clin Med Insights Reprod Health. 2019;13:1179558119828393.
- Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1664–1678.
- Lambertini M, Horicks F, Del Mastro L, et al. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77.
- Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.
- Hyman JH, Tulandi T. Fertility preservation options after gonadotoxic chemotherapy. Clin Med Insights Reprod Health. 2013;7:61–69.
- Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052.
- Lee JH, Choi YS. The role of gonadotropin-releasing hormone agonists in female fertility preservation. Clin Exp Reprod Med. 2021;48(1):11–26.
- Floyd JL, Campbell S, Rauh-Hain JA, et al. Fertility preservation in women with early-stage gynecologic cancer: optimizing oncologic and reproductive outcomes. Int J Gynecol Cancer. 2021;31(3):345–351.